Effects of fucoidan from Fucus vesiculosus in reducing symptoms of osteoarthritis: a randomized placebo-controlled trial
Authors Meyers S, Mulder A, Baker D, Robinson S, Rolfe M, Brooks L, Fitton J H
Received 26 August 2015
Accepted for publication 21 January 2016
Published 26 May 2016 Volume 2016:10 Pages 81—88
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Amol Kavishwar
Peer reviewer comments 2
Editor who approved publication: Dr Doris Benbrook
Stephen P Myers,1 Ann M Mulder,1 Don G Baker,1 Shelley R Robinson,1 Margaret I Rolfe,2 Lyndon Brooks,1 J Helen Fitton,3
1NatMed-Research Unit, Southern Cross University, 2University Centre for Rural Health, Sydney School of Public Health, The University of Sydney, Lismore, NSW, 3Marinova Pty Ltd, Cambridge, TAS, Australia
Purpose: Preliminary investigation of a fucoidan with demonstrated reduction in the symptoms of osteoarthritis (OA) of the hip and knee.
Patients and methods: A double-blind randomized controlled trial was carried out to determine the safety and efficacy of a 300 mg dose of a Fucus vesiculosus extract (85% fucoidan) over a 12-week period in a population (n=122) with mild-to-moderate OA of the hip and knee as measured by the validated instrument "Comprehensive Osteoarthritis Test." Safety was measured by assessing cholesterol, liver function, renal function, and hematopoietic function, and closely monitoring adverse events.
Result: Ninety-six participants completed the study. The reduction in symptoms of OA was not significantly different from the placebo response. There were no changes in the blood measurements that were of any clinical significance during the course of the study.
Conclusion: The F. vesiculosus fucoidan extract was safe and well tolerated. At a dose of 300 mg, the extract showed no difference in reduction of OA symptoms from the placebo.
Keywords: joint pain, clinical trial, seaweed, polysaccharide
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]